C. Pison (Grenoble Cedex 9, France), M. Breyer (Vienna, Austria)
Clinical and inflammatory factors associated with body mass index in COPD patients
Y. Higashimoto, T. Yamagata, N. Honda, Y. Yamagata, H. Satoh, M. Okada, R. Satoh, H. Sano, T. Iwanaga, T. Miyara, M. Muraki, K. Tomita, K. Fukuda, Y. Tohda (Osakasayama, Ito-gun, Japan)
|   |
Elevation of cardiac troponin-I predicts long-term mortality in patients with acute exacerbation of chronic obstructive pulmonary disease
O. Fruchter, M. Yigla (Haifa, Israel)
| |
Mucociliary clearance‘s condition in patients with COPD
T. Pertseva, O. Lykholat, O. Gurzhiy (Dnepropetrovsk, Ukraine)
| |
Platelet activation is enhanced in stable and exacerbated COPD
J. Maclay, D. McAllister, N. Mills, D. Newby, W. MacNee (Edinburgh, United Kingdom)
| |
Serum procalcitonine (PCT) as a marker of respiratory infection by pseudomonas aeruginosa (PA) in patients with COPD or bronchiectasis
V. Giraud, D. Cobarzan, H. Puy, A. Beauchet, B. Heym, T. Chinet (Boulogne, France)
| |
The effects of serum leptin on bone metabolism in chronic obstructive pulmonary disease
E. Kochetkova, Y. Maistrovskay, V. Nevzorova, R. Kessler, G. Massard (Strasbourg, France; Vladivostok, Russian Federation)
| |
Airway and systemic inflammation profile in current smokers controls, COPD current smokers and COPD ex-smokers
S. Tanni, N. Pelegrino, R. Amaral, A. Angeleli, C. Correa, I. Godoy (Botucatu, Brazil)
| |
Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study
V. Pinto-Plata, C. Casanova, J. P. De Torres, H. Müllerova, H. Corado, N. Varo, E. Cordoba, H. Paz, S. Zeineldine, B. Celli (Boston, United States Of America; Tenerife, Pamplona, Spain; London, United Kingdom)
| |
Effect of the matrix metalloproteinase-9 on bone in chronic obstructive pulmonary disease
E. Kochetkova, U. Maistrovskay, S. Albavichus, T. Tilik, G. Massard, R. Kessler (Strasbourg, France; Vladivostok, Russian Federation)
| |
Are copeptin levels high in COPD acute attack?
N. Bekar, A. Uysal, M. Sancak, G. Aras, F. Kadakal, V. Yilmaz (Turkey)
| |
Increased expression of tenascin-c and α smooth muscle actin in large airways in COPD
M. Lofdahl, R. Kaarteenaho, E. Lappiblanco, M. Mikko, G. Tornling, M. Skold (Uppsala, Stockholm, Sweden; Oulu, Finland)
| |
Vitamin D deficiency and FEV1 decline in COPD
J. Quint, G. Donaldson, J. Goldring, N. Wassef, M. Thomas, J. Wedzicha (London, United Kingdom)
| |
The role of leptin and adiponectin in patients with COPD
D. Kim, S. Paik (Bucheon, Republic Of Korea)
| |
Influence of tobacco-smoking and it intensification on systemic inflammatory state (sis) in COPD patients
T. Pertseva, L. Konopkina (Dnipropetrovsk, Ukraine)
| |
Microalbuminuria in patients with COPD: prevalence and correlations with pulmonary parameters
C. Casanova, J. P. De Torres, J. Navarro, A. Aguirre-Jaime, P. Toledo, E. Cordova, R. Baz, B. Celli (Santa Cruz de Tenerife, Pamplona, Spain; Boston, United States Of America)
| |
Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels
M. Zeng, X. Huang, Y. Li, L. Liu, S. Huang, H. Wang (Guangzhou, China)
| |